p21 (WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo

Oral Oncology

Volumn 34, Issue 3, 1998, Pages 211-218

  Cardinali, M ^a,c   Jakus, J ^a   Shah, S ^a   Ensley, J F ^b   Robbins, K C ^a   Yeudall, W A ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c Division of Bacterial Products   (United States)

Author keywords

Cell cycle; Cip1; Gene therapy; Oral cancer; P21; sdil; Tumour suppressor; WAF1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; PROTEIN P21; VIRUS VECTOR;

ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; NUDE MOUSE; PRIORITY JOURNAL; RETROVIRUS; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; MOUTH NEOPLASMS; NEOPLASM TRANSPLANTATION; RETROVIRIDAE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0032078707     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1368-8375(97)00083-3     Document Type: Article

References (71)

1. [1] Hartwell L, Weinert T. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629-634.
2. [2] Pines J, Hunter T. Cyclins and cancer II. Cyclin D and CDK inhibitors come of age. Cell 1994;79:573-582.
3. [3] Pines J. The cell cycle kinases. Seminars in Cancer Biology 1994;5:305-313.
4. [4] Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes and Development 1995;9:1149-1163.
5. [5] Yeudall WA, Jakus J. Cyclin kinase inhibitors add a new dimension to cell cycle control. Oral Oncology, European Journal of Cancer 1995;31B:291-298.
6. 14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes and Development 1994;9:2939-2952.
7. INK4B/MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Research 1995;55:1448-1451.
8. [8] Kamb A, Gruis NA, Weaver-Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumour types. Science 1994;264:436-440.
9. [9] Liu Q, Neuhausen S, McClure M, et al. CDKN2 (MTS1) tumour suppressor gene mutations in human tumour cell lines. Oncogene 1995;10:1061-1067.
10. [10] Merlo A, Herman JG, Mao L, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nature Medicine 1995;1: 686-692.
11. ink4. Science 1995;267:249-252.
12. INK4A,MTS1) gene and other loci on human chromosome 9. International Journal of Cancer 1996;65:840-846.
13. [13] Liggett WH Jr, Sewell DA, Rocco J, et al. p16 and p16b are potent growth suppressors of head and neck squamous carcinoma cells in vitro. Cancer Research 1996;56:4119-4123.
14. [14] Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-816.
15. [15] El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumour suppression. Cell 1993;75:817-825.
16. [16] Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Experimental Cell Research 1994;211: 90-98.
17. [17] El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Research 1994;54:1169-1174.
18. [18] Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 1994;369:574-578.
19. [19] Li R, Waga S, Hannon GJ, Beach D, Stillman B. Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. Nature 1994;371:534-537.
20. [20] Strausfeld UP, Howell M, Rempel R, et al. Cip1 blocks the initiation of DNA replication in Xenopus extracts by inhibition of cyclin-dependent kinases. Current Biology 1994;4:876-883.
21. [21] Shivji MKK, Grey SJ, Strausfeld UP, Wood RD, Blow JJ. Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision repair. Current Biology 1994;4:1062-1068.
22. [22] Harris CC. p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1981.
23. [23] Lane DP. p53: guardian of the genome. Nature 1992;358:15-16.
24. [24] Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J. Growth inhibition by TGFβ linked to suppression of retinoblastoma protein phosphorylation. Cell 1990;62:175-185.
25. [25] Howe PH, Draetta G, Leof EB. Transforming growth factor b1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S phase growth arrest. Molecular and Cell Science 1991;11:1185-1194.
26. [26] Ewen ME, Sluss HK, Whitehouse LL, Livingston DM. TGFβ inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell 1993;74:1009-1020.
27. [27] Geng Y, Weinberg RA. Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependent protein kinases. Proceedings of the National Academy of Science USA 1993;90: 10315-10319.
28. [28] Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF-beta. Science 1993;260:536-539.
29. INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994;371:257-260.
30. [30] Li C-Y, Suardet L, Little JB. Potential role of WAF1/Cip1/p21 as a mediator of TGF-β cytoinhibitory effect. Journal of Biological Chemistry 1995;270:4971-4974.
31. [31] Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang X-F. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proceedings of the National Academy of Science USA 1995;92: 5545-5549.
32. WAF1 induction are important early events. Cell Growth and Differentiation 1996;7:1291-1304.
33. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes and Development 1994;8:9-22.
34. [34] Reynisdottir I, Polyak K, Iavarone A, Massague J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes and Development 1995;9:1831-1845.
35. [35] National Cancer Institute, Cancer Statistics Review: 1973-1988, NCI. Division of Cancer Prevention and Control, Surveillance Program. NIH publication 91-2789, Bethesda, Maryland, 1991.
36. [36] Somers KD, Merrick MA, Lopez ME, et al. Frequent p53 mutations in head and neck cancer. Cancer Research 1992;52:5997-6000.
37. [37] Burns JE, Baird MC, Clark LJ, et al. Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. British Journal of Cancer 1993;67:1274-1284.
38. [38] Brachman DG, Graves D, Vokes E, et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Research 1992;52:4832-4836.
39. [39] Game SM, Huelsen A, Patel V, et al. Progressive abrogation of TGF-β1 and EGF growth control is associated with tumour progression in ras-transfected human keratinocytes. International Journal of Cancer 1992;52:461-470.
40. [40] Prime SS, Matthews JB, Patel V, et al. TGF-β receptor regulation mediates the response to exogenous ligand but is independent of the degree of cellular differentiation in human oral keratinocytes. International Journal of Cancer 1994;56:406-412.
41. [41] Garrigue-Antar L, Munoz-Antonia T, Antonia SJ, et al. Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Research 1995;55:3982-3987.
42. [42] Cardinali M, Pietraszkiewicz H, Ensley JF, Robbins KC. Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. International Journal of Cancer 1995;61:98-103.
43. [43] Yeudall WA, Crawford RY, Ensley JF, Robbins KC. MTS1/ CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis 1994;15:2683-2686.
44. [44] Parkinson EK, Yeudall WA. The culture of primary tumours from human epidermis. Developmental Oncology 1991;64:187-197.
45. [45] Mann R, Mulligan RC, Baltimore D. Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 1983;33:153-159.
46. [46] Miller AD, Rosman GJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989;7:980-990.
47. [47] Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Research 1990;18:3587-3596.
48. [48] Wigler M, Pellicer A, Silverstein S, et al. DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. Proceedings of the National Academy of Science USA 1979;76:1373-1376.
49. [49] Munck JN, Cvitkovic E, Piekarski JD, et al. Computed tomographic density of metastatic lymph nodes as a treatment related prognostic factor in advanced head and neck cancer. Journal of the National Cancer Institute 1991;83:569-575.
50. [50] Janot F, Cvitkovic E, Piekarski JD, et al. Correlation between nodal density in contrasted scans and response to cisplatinum-based chemotherapy in head and neck squamous cell cancer; a prospective validation. Head and Neck 1993;15:222-229.
51. Cip1 in muscle and other terminally differentiating cells. Science 1995;267:1024-1027.
52. [52] Halevy O, Novitch BG, Spicer DB, et al. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 1995;267:1018-1021.
53. [53] Jakus J, Yeudall WA. Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Oncogene 1996;12:2369-2376.
54. [54] Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP. The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumour progression. Genes and Development 1996;10:3065-3075.
55. [55] Blagosklonny MV, El-Deiry WS. In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. International Journal of Cancer 1996;67:386-392.
56. [56] Hamada K, Alemany R, Zhang WW, et al. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Research 1996;56:3047-3054.
57. [57] Harris MP, Sutjipto S, Wills KN, et al. Adenovirus-mediated p53 gene transfer inhibits growth of human tumour cells expressing mutant p53 protein. Cancer Gene Therapy 1996;3:121-130.
58. [58] Eastham JA, Hall SJ, Sehgal I, et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Research 1995;55:5151-5155.
59. [59] Clayman GL, Liu TJ, Overholt SM, et al. Gene therapy for head and neck cancer. Comparing the tumour suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21). Archives of Otolaryngology, Head and Neck Surgery 1996;122:489-493.
60. [60] Eliyahu D, Michaelovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M. Wild-type p53 can inhibit oncogene-mediated focus formation. Proceedings of the National Academy of Science USA 1989;86:8763-8767.
61. [61] Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell 1989;57:1083-1093.
62. [62] Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
63. [63] Clark AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-852.
64. [64] Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-849.
65. [65] Cirielli C, Riccioni T, Yang C, et al. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. International Journal of Cancer 1995;63:673-679.
66. [66] Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumourigenesis of prostatic tumour cells. Cancer Research 1995;55:4210-4213.
67. [67] Liu TJ, El-Naggar AK, McDonnell TJ, et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Research 1995;55:3117-3122.
68. [68] Chen J, Willingham T, Shuford M, et al. Effects of ectopic over-expression of p21 (WAF1/CIP1) on aneuploidy and the malignant phenotype of human brain tumour cells. Oncogene 1996;13:1395-1403.
69. [69] Patel V, Jakus J, Harris CM, Ensley JF, Robbins KC, Yeudall WA. Altered expression and activity of G1/S cyclins and cyclin dependent kinases characterize squamous cell carcinomas of the head and neck. International Journal of Cancer (in press).
70. [70] Ensley JF, Maciorowski Z. Clinical application of DNA content parameters in patients with squamous cell carcinomas of the head and neck. Seminars in Oncology 1994;21:330-339.
71. [71] Ensley JF. The clinical application of DNA content and kinetic parameters in the treatment of patients with squamous cell carcinomas of the head and neck. Cancer Metastases Reviews 1996;15:133-141.